JAK2 mutation in a boy with polycythemia vera, but not in other pediatric hematologic disorders [8]

Leukemia

Volumn 20, Issue 8, 2006, Pages 1453-1454

  Park, M J ^a   Shimada, A ^a   Asada, H ^b   Koike, K ^c   Tsuchida, M ^c   Hayashi, Y ^a  

^a Gunma Children's Medical Center   (Japan)

^b Iwaki Kyouritsu General Hospital   (Japan)

^c Ibaraki Children's Hospital   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

JANUS KINASE 2;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ACUTE MEGAKARYOCYTIC LEUKEMIA; ADOLESCENT; CANCER CELL CULTURE; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DOWN SYNDROME; ERYTHROCYTOSIS; GENE MUTATION; HEMATOLOGIC DISEASE; HUMAN; HUMAN CELL; JUVENILE MYELOMONOCYTIC LEUKEMIA; LETTER; MALE; MYELODYSPLASTIC SYNDROME; MYELOPOIESIS; PHYSICAL EXAMINATION; POLYCYTHEMIA VERA; POLYMERASE CHAIN REACTION; PREVALENCE; PRIORITY JOURNAL;

EID: 33746109984     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/sj.leu.2404259     Document Type: Letter

References (8)

1. Baxter EJ, Scott LM, Campbell PJ, East C, Fourouclas N, Swanton S et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 2005; 365: 1054-1061.
2. Kralovics R, Passamonti F, Buser AS, Teo SS, Tiedt R, Passweg JR et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 2005; 352: 1779-1790.
3. James C, Ugo V, Le Couedic JP, Staerk J, Delhommeau F, Lacout C et al. A unique clonal JAK2 mutation leading to constitutive signaling causes polycythaemia vera. Nature 2005; 434: 1144-1148.
4. Tono C, Xu G, Toki T, Takahashi Y, Sasaki S, Terui K et al. JAK2 Val617Phe activating tyrosine kinase mutation in juvenile myelomonocytic leukemia. Leukemia 2005; 19: 1843-1844.
5. Scott LM, Campbell PJ, Baxter EJ, Todd T, Stephens P, Edkins S et al. The V617F JAK2 mutation is uncommon in cancers and in myeloid malignancies other than the classic myeloproliferative disorders. Blood 2005; 106: 2920-2921.
6. Shimada A, Taki T, Tabuchi K, Tawa A, Horibe K, Tsuchida M et al. KIT mutations, and not FLT3 internal tandem duplication, are strongly associated with a poor prognosis in pediatric acute myeloid leukemia with t(8;21): A study of the Japanese Childhood AML Cooperative Study Group. Blood 2006; 107: 1806-1809.
7. James C, Delhommeau F, Marzac C, Teyssandier I, Couedic JP, Giraudier S et al. Detection of JAK2 V617F as a first intention diagnostic test for erythrocytosis. Leukemia 2005; 20: 350-353.
8. Levine RL, Loriaux M, Huntly BJ, Loh ML, Beran M, Stoffregen E et al. The JAK2V617F activating mutation occurs in chronic myelomonocytic leukemia and acute myeloid leukemia, but not in acute lymphoblastic leukemia or chronic lymphocytic leukemia. Blood 2005; 106: 3377-3379.